

**TITLE**

The effect of medical grade compression garments on the repeated-bout effect in non-resistance trained men

**AUTHOR**

Brown, Freddy; Hill, Matt; Renshaw, Derek; et al.

**JOURNAL**

Experimental Physiology

**DATE DEPOSITED**

27 September 2023

**This version available at**

<https://research.stmarys.ac.uk/id/eprint/6077/>

---

**COPYRIGHT AND REUSE**

Open Research Archive makes this work available, in accordance with publisher policies, for research purposes.

**VERSIONS**

The version presented here may differ from the published version. For citation purposes, please consult the published version for pagination, volume/issue and date of publication.

1 **The effect of medical grade compression garments on the repeated-bout effect in non-**  
2 **resistance trained men**

3 Freddy Brown MSc <sup>1,2</sup>, Matt Hill, Ph.D.<sup>1,2</sup>, Derek Renshaw Ph.D.<sup>2</sup>, Charles Pedlar <sup>3,4</sup>, Ph.D.,  
4 Jessica Hill., Ph.D.<sup>3</sup>, Ken van Someren <sup>5</sup>, Glyn Howatson <sup>6,7</sup>, Jason Tallis, Ph.D.<sup>1,2</sup>

5

6 <sup>1</sup> Faculty of Health and Life Sciences, Coventry University, Coventry, UK

7 <sup>2</sup> Centre for Sport, Exercise and Life Sciences (CSELS), Coventry University, Coventry, UK

8 <sup>3</sup> Faculty of Sport, Health and Applied Science, St Mary's University, Twickenham, UK

9 <sup>4</sup> Institute of Sport, Exercise and Health, Division of Surgery and Interventional Science,  
10 University College London, London, UK

11 <sup>5</sup> Sports Lab Northwest, Atlantic Technological University, Donegal, Ireland

12 <sup>6</sup> Faculty of Health and Life of Sciences, Northumbria University, Newcastle Upon Tyne, UK

13 <sup>7</sup> Water Research Group, Northwest University, Potchefstroom, South Africa

14

15 Coventry University Ethics Committee Ref P93660

16

17 Corresponding author:

18 Freddy Brown,

19 Coventry University,

20 Room 1.31, Alison Gingell Building,

21 Whitefriars Street, Coventry, CV1 2DS

22 Email: [ad1385@coventry.ac.uk](mailto:ad1385@coventry.ac.uk)

23 Key Words: Adaptation, Recovery, Compression, Performance, Strength, Muscle damage

24 Running title: Compression garments and the repeated bout effect

25

26 Word count: 4934 (6899 including references, figure titles and legends)

27 Abstract word count: 249

28

29

30 **The effect of medical grade compression garments on the repeated-bout effect in non-**  
31 **resistance trained men**

32

33 Key Words: Adaptation, Recovery, Compression, Performance, Strength, Muscle damage

34

35 Running title: Compression garments and the repeated bout effect

36

37 Word count: 4938 (6903, including references, figure titles and legends)

38 Abstract word count: 249

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55 **Abstract**

56 Whilst compression garments (CG) may enhance recovery from exercise-induced muscle  
57 damage (EIMD), many recovery strategies can attenuate adaptative responses. Therefore, the  
58 effects of CG on recovery from EIMD, and the rapid protective adaptations known as the  
59 repeated bout effect (RBE) were investigated. Thirty-four non-resistance trained males (18–45  
60 y) randomly received class II medical-grade CG or placebo for 72 h following eccentrically-  
61 focused lower-body exercise, in a double-blind, randomised controlled trial. Indices of EIMD  
62 were assessed at baseline, 0, 24, 48 and 72 h post-exercise, before exercise and testing were  
63 repeated after 14 d. Results were analysed using a three-way (time x condition x bout) linear  
64 mixed-effects model. Exercise impaired isometric and isokinetic strength, with soreness and  
65 thigh circumference elevated for 72 h ( $p < 0.001$ ). Compression did not enhance recovery ( $p >$   
66  $0.05$ ), despite small to moderate effect sizes (ES, reported alongside 90% confidence intervals)  
67 for isokinetic strength (ES from 0.2 [-0.41, 0.82] to 0.65 [0.03, 1.28]). All variables recovered  
68 faster after the repeated bout ( $p < 0.005$ ). However, RBE for peak isokinetic force was impaired  
69 in CG at  $60^{\circ}.s^{-1}$  (group x bout interaction:  $\chi^2 = 4.24$ ,  $p = 0.0395$ ; ES = -0.56 [-1.18, 0.07]) and  
70 completely absent at  $120^{\circ}.s^{-1}$  ( $\chi^2 = 16.2$ ,  $p < 0.001$ , ES = -0.96 [-1.61, -0.32]) and  $180^{\circ}.s^{-1}$  ( $\chi^2 = 10.4$ ,  
71  $p = 0.001$ , ES = -0.72 [-1.35, -0.09]). Compression blunted RBE at higher isokinetic velocities  
72 without improving recovery in non-resistance trained males, potentially contraindicating their  
73 use following unaccustomed exercise in this population.

74

75 **New findings:**

76 The study sought to determine the effects of compression garments on recovery from  
77 unaccustomed damaging exercise, and subsequent protective adaptations. Compression did not  
78 influence recovery, but was associated with blunted protective adaptations for isokinetic  
79 performance, which were completely absent at high velocities. Based on these findings, the use  
80 of CG for recovery would not be recommended following unaccustomed exercise, particularly if  
81 the maintenance of high-velocity performance following EIMD is desirable.

82

83

84

85 **Introduction**

86 The concept of recovery describes the reestablishment of post-exercise performance, with  
87 important implications for recreational exercisers and athletes alike (Peake, 2019; Skorski et al.,  
88 2019). Sufficient recovery allows athletes to achieve and maintain an optimal training stimulus  
89 (Peake, 2019; Skorski et al., 2019), whilst perceptual symptoms of under-recovery may reduce  
90 adherence in recreational exercisers (Flack, Johnson, & Roemmich, 2017). Importantly,  
91 however, some anti-inflammatory and/or antioxidant recovery strategies have been shown to  
92 ameliorate the physiological stressors required for muscular adaptation (Figueiredo et al., 2016;  
93 Peake, 2019). The use of particular recovery strategies may therefore represent a compromise  
94 between optimising short-term recovery and maximising the response to training.

95

96 The time-course of post-exercise recovery depends upon the specific physiological demands of  
97 an exercise bout (Skorski et al., 2019), with exercise-induced muscle damage (EIMD)  
98 contributing to prolonged declines in muscular performance (Nosaka, Chapman, Newton, &  
99 Sacco, 2006). Describing the disruption of muscle fibres and associated reductions in contractile  
100 force, EIMD may be associated with strength deficits of up to 30% in untrained participants  
101 (Clarkson & Hubal, 2002; Nosaka et al., 2006) and is most commonly caused by unaccustomed,  
102 eccentric (muscle-lengthening) exercise, such as plyometrics, resistance exercise and running  
103 (Brown et al., 2017; Goto & Morishima, 2014; Hill et al., 2017; Thomas, Ziogas, Smith, Zhang, &  
104 Londeree, 1995). The progression of EIMD is mediated by post-exercise inflammation (Deyhle et  
105 al., 2016; Hyldahl, Chen, & Nosaka, 2017), with symptoms such as soreness and impaired  
106 mobility persisting for up to 10 days (Clarkson & Hubal, 2002). One seemingly effective recovery  
107 strategy for EIMD is the use of compression garments (CG), which has been associated with  
108 ameliorated strength losses, swelling and cellular disruption in both trained and untrained  
109 participants (Brown et al., 2017; Marques-Jimenez, Calleja-Gonzalez, Arratibel, Delextrat, &  
110 Terrados, 2016). However, the effects of CG on adaptation have received little attention (Baum,  
111 Carter, Neufeld, & Dolezal, 2020; Edgar, Beaven, Gill, & Driller, 2022). Robust data on the effects  
112 of compression on muscular adaptation are required to guide the use of CG for recovery.

113

114 Muscle-damaging exercise is unique in that as little as a single exposure may elicit adaptations  
115 which confer protection from subsequent bouts (Hyldahl et al., 2017). This “repeated bout

116 effect” (RBE) may be observed after as little as three days and is most pronounced following  
117 unaccustomed exercise (Chen & Nosaka, 2006; Hyldahl et al., 2017). Although the mechanisms  
118 responsible for RBE are unclear, post-exercise inflammation is thought to at least partially  
119 mediate the protective adaptations and modified inflammatory responses to EIMD (Deyhle et  
120 al., 2016; Hyldahl et al., 2017). Importantly, researchers have suggested that the benefits of CG  
121 may be related to an ameliorative effect on local inflammation (Hill et al., 2017; Peake, 2019),  
122 with anti-inflammatory effects reported in both sporting (Valle et al., 2013) and clinical settings  
123 (Beidler et al., 2009). As compression may influence mediators of the repeated bout effect, the  
124 effects of CG on RBE require further investigation.

125

126 Whilst the use of CG for recovery from EIMD is supported by academic consensus, the literature  
127 is still beset by the varied quality of supporting evidence (Brown et al., 2017; Marques-Jimenez  
128 et al., 2016). For example, most studies have failed to implement a placebo or sham condition  
129 (reviewed by Brown et al., 2017), or where used, to report on the effectiveness of blinding  
130 (Brown et al., 2017; de Glanville & Hamlin, 2012; Hill et al., 2017). The few double-blind studies  
131 that exist have compared CG to non-compressive garments - a “sham treatment” of  
132 questionable efficacy (Baum et al., 2020; de Glanville & Hamlin, 2012). Although previous meta-  
133 analyses have reported large benefits to strength recovery when CG are worn following EIMD  
134 (Brown et al., 2017; Marques-Jimenez et al., 2016), the placebo effect can explain benefits of  
135 this magnitude (Clark, Hopkins, Hawley, & Burke, 2000). Such issues prevent researchers from  
136 making informed, quantitative judgements on the benefits of CG, compared with the potential  
137 risks to adaptation. Accordingly, the aims of this investigation were to examine the effects of CG  
138 on recovery from EIMD using a double-blind approach, and to determine the effects of  
139 compression on RBE in non-resistance trained participants. Given the ambiguity of existing  
140 evidence and uncertainties over the mechanisms involved, results were compared to a two-  
141 tailed null hypothesis - that no differences in recovery or RBE would be observed.

142

143

144

145

146 **Materials and methods**

147 **Ethical approval**

148 Institutional ethics approval was obtained from Coventry University Ethics Board (Ref P93660)  
149 before written informed consent was provided by all participants. The study conformed to the  
150 standards set by the Declaration of Helsinki, except for registration in a database.

151

152 **Design**

153 The effects of CG on muscular recovery and RBE following EIMD were assessed using a double-  
154 blind, 3-way (condition x time x bout) design. Analysis was performed unblinded to allow  
155 assessment of participant adherence. Performance measures and indices of EIMD were taken at  
156 baseline, then at 0, 24, 48 and 72 h ( $\pm$  2 h) after an initial bout of exercise (B1) to assess recovery  
157 in participants wearing CG or taking placebo (PLA). A repeated bout (B2) was completed after  
158 14 d without any recovery intervention, and recovery monitored at the same time-points. To  
159 account for the highly individual (Clarkson & Hubal, 2002; Hyldahl et al., 2017), and potentially  
160 sex-specific (Fernandez-Gonzalo, Lundberg, Alvarez-Alvarez, & de Paz, 2014), nature of EIMD  
161 responses, only male participants were recruited, and pair-matched following familiarization  
162 according to body mass and the number of weekly exercise bouts of various types that were  
163 undertaken (self-report). Exercise was categorised into running, non-load bearing exercise  
164 (swimming and cycling) and multi-directional exercise (e.g. team sports) to account for the  
165 protective effects of prior damage, which is greater following load-bearing activity (Thomas et  
166 al., 1995). Participants were also matched by body mass to control for the effects of total work  
167 and eccentric forces on EIMD responses to the load-bearing exercise challenge employed  
168 (depth-jumps) (Paschalis, Koutedakis, Jamurtas, Mougios, & Baltzopoulos, 2005). Participants  
169 were then randomly assigned to either group, using open-access statistical software ('optmatch'  
170 package, R Foundation for Statistical Computing, Vienna, Austria).

171

172 **Participants**

173 Selecting an alpha value of 0.05 with 80% statistical power, a sample size calculation was carried  
174 out with the G\*Power software package (version 3.1.9.7, Heinrich Heine University, Düsseldorf,  
175 Germany), based upon an expected Cohen's d effect size of 1 from previous studies assessing

176 the effects of CG on recovery from EIMD on knee-extension performance (Goto & Morishima,  
177 2014; Hill et al., 2017). While a matched-pair design required a minimum sample of  $n = 10$  ( $2 \times$   
178  $n = 5$ ), a conservative estimate of 34 ( $2 \times n = 17$ ) was chosen, based on an independent group  
179 design. Accordingly, 34 males (18–45 y) who met national physical activity guidelines (Care,  
180 2019) were recruited. Those who had completed lower-body resistance exercise within 6  
181 months were excluded to maximise the likelihood of observing RBE (Deyhle et al., 2016; Hyldahl  
182 et al., 2017), as were participants whose habitual exercise had been disrupted by injury for at  
183 least one week of the preceding 28 days. Participants were asked to refrain from taking NSAIDs  
184 or supplements (including antioxidants and whey protein) throughout testing, from 48 h before  
185 the start of the study.

186

## 187 **Procedures**

188 Familiarization was conducted over two sessions, 1-2 weeks before the trial. Body mass was  
189 measured (seca 875 Class III scales, seca Medical Measuring Systems, Birmingham UK), before  
190 anthropometry was assessed in accordance with the recommendations of the International  
191 Society for the Advancement of Kinanthropometry by a level 1 practitioner. Skinfolds ( $\Sigma 8$ ), mid-  
192 thigh girth (MTG) and calf circumference were measured in a standing position, with the latter  
193 used to guide the selection of appropriately sized British class II (moderate) compression  
194 stockings, according to manufacturer guidelines (DUOMED soft thigh length compression  
195 stockings, Medi UK Ltd., Hereford, UK). Subsequently, CG were measured for applied pressures  
196 in all participants (Picopress, Microlab, Padua, Italy) at the mid-thigh, medial calf, ankle (Bjork &  
197 Ehmann, 2019), and “manufacturer’s B1 point” (MB1) (Uhl, Benigni, & Cornu-Thenard, 2013).  
198 To ensure physiologically relevant pressures, smaller CG were provided if stockings failed to  
199 apply 14 mmHg at the thigh; a proposed threshold in the literature (Hill, Howatson, van  
200 Someren, Davidson, & Pedlar, 2015). The entire battery of performance tests was then  
201 completed in the same order as subsequent experimental trials (Brown et al., 2022).

202

203 After a standardised warm-up (3 min cycling at 100 W; 10 repetitions of body-weight squats,  
204 lunges on either leg and countermovement jumps), peak force was assessed from three (5 s)  
205 maximal isometric voluntary contractions (MIVC) of the knee extensors at 85° flexion (KinCom,  
206 Chattanooga, TN, USA – 100 Hz), followed by three consecutive isokinetic contractions at each



207 of 60 °.s<sup>-1</sup> 120 °.s<sup>-1</sup> and 180 °.s<sup>-1</sup> (Figure 1). Participants sat reclined at 15°, were secured with  
208 straps, and were prevented from gripping the chair during contractions. Finally, peak power  
209 output in the 6 s cycle sprint test (PPT) was assessed in a standing position from a stationary  
210 start (Brown et al., 2022). Participants were positioned so that the knee was just flexed at the  
211 bottom of the stroke when seated (handlebars adjusted for comfort), with settings recorded and  
212 repeated for each visit. Resistance was determined from manufacturer settings (Wattbike Pro,  
213 Wattbike Ltd., Nottingham, UK). Verbal encouragement was given for all tests. A minimum of  
214 three repetitions per test was completed during each familiarization session, or until  
215 performance plateaued as defined by the final two efforts resulting in coefficients of variation  
216 (CV) ≤ 5%. Between day reliability values (CV) were 6% for MVIC and 9.4%, 3.5% and 7.5% for  
217 peak isokinetic force at 60°.s<sup>-1</sup>, 120°.s<sup>-1</sup> and 180°.s<sup>-1</sup>, respectively. Within session CVs were 6%,  
218 8.9%, 5.5%, 5.4%. Peak cycle sprint power was described by CVs of 4.8% and 3.9% for between-  
219 day and within-session values, respectively.

220

221 At baseline, soreness, MTG and capillary blood samples from the finger were taken as previously  
222 described (Brown, Hill, van Someren, Howatson, & Pedlar, 2021), with changes in MTG taken as  
223 a measure of post-exercise swelling (Brown et al., 2017; Goto & Morishima, 2014; Marques-  
224 Jimenez et al., 2016). Performance was assessed as above, taking peak values from the best of  
225 three attempts separated by 90 s recovery. Serum was assessed for creatine kinase activity ([CK])  
226 using spectrophotometric assay with a between-run precision of < 1%, as determined in our  
227 laboratory (CK-NAC, RX Daytona, Randox, County Antrim, Northern Ireland). A repeated sprint  
228 protocol (Duffield, Cannon, & King, 2010) (20 x 20 m sprints with a 5 m deceleration) followed  
229 by 10 sets of 10 depth-jumps (DJs) was then completed (Hill et al., 2017) to induce EIMD (Figure  
230 1). Participants completed sprints every 60 s, with sprint times (TC PhotoGate, Brower timing  
231 Systems, Utah, USA) relayed to participants to encourage maximal effort. Sets of 10 DJs were  
232 completed every 2.5 min from a 0.6 m box onto two force plates sampling at 1000 Hz (AMTI  
233 BP900900, Watertown, MA, USA) to measure vertical ground reaction forces. Jump height was  
234 determined from take-off velocity for each jump using forward integration (McMahon, Lake,  
235 Stratford, & Comfort, 2021), first calculating impact velocity from the 0.6 m descent. Peak and  
236 average forces during braking and propulsion, as well as the work performed for each jump  
237 (equivalent to the sum of average braking and propulsive forces multiplied by  
238 countermovement depth), were calculated to characterise the exercise challenge (Table 2),

239 alongside starting and peak heart rates for each sprint and set of DJs (S810i™, Polar, Kempele,  
240 Finland). Participants told they would have to repeat any sprint where they continued beyond  
241 the marked 5 m deceleration zone, and any DJ for which the knee angle at the bottom of the  
242 jump failed to reach 90° flexion.

243

244 Following B1, participants received either CG or placebo tablets providing < 0.1 g carbohydrate  
245 (6 mm hard lactose/sucrose tablets, HSC, Holt, UK) and instructed to either consume a tablet or  
246 don CG in private before leaving the building. Garments were worn for 72 h post-exercise, with  
247 participants instructed to remove CG only to wash, and before arriving for subsequent testing.  
248 Participants assigned to PLA were given 3 tablets to consume (daily) immediately after testing,  
249 having been told by a researcher that they contained magnesium to aid recovery. Participants  
250 were randomised into groups A and B by the lead researcher, and informed of their specific  
251 interventions by a third party. To aid placebo blinding, participants were told there was an  
252 additional control group (group C) for comparison. This group did not exist, and participants  
253 were informed of this deception at the conclusion of data collection. Participants were  
254 requested to record their dietary intake from the day before the trial until 72 h post-exercise,  
255 and to replicate this for the repeated bout. The effectiveness of blinding was assessed at the  
256 conclusion of the trial by asking participants to rate their intervention for perceived efficacy from  
257 0 to 10, accepting half-marks (Karanicolas, Farrokhyar, & Bhandari, 2010). Finally, baseline  
258 performance tests, eccentrically-focused exercise and assessments of recovery were repeated  
259 after 14 d to investigate RBE.

260

261


262

263

264

265

266



**Figure 1. Study design and procedures**

## 282 **Statistical analysis**

283 An open-access statistical software package was used for all statistical analyses (R Foundation  
284 for Statistical Computing, Vienna, Austria), which were carried out on raw data (although  
285 changes in MTG were graphically presented as normalised values for clarity). Despite initial  
286 efforts at pair-matching, follow-up questioning on adherence revealed that one participant  
287 mistakenly took the wrong allocation, resulting in  $n = 18$  and  $n = 16$  for CG and PLA, respectively.  
288 Accordingly, a between-group design was employed, using a linear mixed effects model with  
289 random intercepts for each participant to account for individual variation in EIMD (Gandotra et  
290 al., 2021). The consideration of random effects in a statistical model also allows for participants  
291 to be included up until the point of withdrawal to enhance statistical power and reduce sample  
292 bias (Nich & Carroll, 2002). Visually comparing fitted and observed values, and calculating root  
293 mean squared error (RMSE) from residuals, revealed this model better matched observed data  
294 for every variable compared with analysis of variance (ANOVA). The assumption of normality  
295 was verified by running QQ plots on residual values, with the mixed effects model independent  
296 of the assumption of sphericity. *Post hoc* testing was carried out with the 'emmeans' package,  
297 adjusting for multiple comparisons (Gandotra et al., 2021). Ordinal soreness data were assessed  
298 with a non-parametric alternative to the split-plot ANOVA (Feys, 2016). All values were reported  
299 as means  $\pm$  SD. Additionally, effect sizes (ES - Cohen's  $d$ ) were calculated as between-group  
300 differences in changes from baseline, and reported alongside 90% confidence intervals as (ES  
301 [LCL, UCL]), where LCL and UCL represent lower and upper 90% confidence limits. Effect sizes  
302 were defined as trivial/small, moderate or large using thresholds of  $\geq 0.2$ ,  $\geq 0.5$  and  $\geq 0.8$ ,  
303 respectively (Batterham & Hopkins, 2006). *Post hoc* power assessments were carried out for all  
304 performance tests using G\*Power.

305

## 306 **Results**

307 Due to COVID-19 pandemic restrictions ( $n = 1$ ) and injuries during the second exercise bout ( $n =$   
308  $2$ ), data on the repeated bout were missing for three participants (CG,  $n = 1$ ; PLA,  $n = 2$ ). Baseline  
309 participant characteristics and garment pressures are detailed below, alongside exercise  
310 responses (Tables 1-2), which did not differ between bouts or groups at either time-point ( $p >$   
311  $0.05$ ). Perceived efficacy did not differ ( $p = 0.558$ ) between CG ( $5 \pm 2$ ) and PLA ( $4.5 \pm 2$ ),  
312 suggesting blinding was effective. Stockings were worn for  $20.9 \pm 3.7$  h.d<sup>-1</sup>, while participants in  
313 PLA each consumed all three tablets.

314

315 Muscle damage and RBE were apparent from post-exercise declines in all isometric and  
316 isokinetic strength measurements, which were attenuated between bouts, and recovered more  
317 rapidly in B2 (Figure 2). For MVIC, significant effects were observed for time ( $\chi^2 = 268, p < 0.001$ ),  
318 bout ( $\chi^2 = 84.3, p < 0.001$ ) and their interaction ( $\chi^2 = 15.6, p = 0.004$ ), without differences  
319 between groups ( $p > 0.05$  – Figure 2). Performance was impaired for 72 h following B1 (post –  
320 48 h:  $p < 0.001$ ; 72h,  $p = 0.006$ ) but had recovered by 48 h after B2 ( $p = 1$  at each time-point –  
321 Supplementary Table), with peak force higher at all post-exercise timepoints ( $p < 0.001$  to 0.005).

322

323 Peak isokinetic forces at 60 °.s<sup>-1</sup>, 120 °.s<sup>-1</sup> and 180 °.s<sup>-1</sup> (Figure 2) were subject to significant  
324 effects ( $p < 0.001$ ) of time ( $\chi^2 = 182, 184$  and  $92.7$  respectively) and bout ( $\chi^2 = 22.6, 15.0, 14.0$ ),  
325 as well as time x bout interactions ( $\chi^2 = 35.1, 36.7, 25.0$ ). Demonstrating RBE, performance  
326 following B1 was impaired for 72 h at each velocity ( $p < 0.001$ ), whereas strength recovered by  
327 24 h following B2 ( $p = 0.1165, p = 0.3568, p = 1$ ). Accordingly, peak force was greater in B2 at  
328 each velocity from 24 – 72 h post-exercise ( $p < 0.001$  to 0.0186). Of note, baseline performance  
329 was also lower ( $p = 0.0071, p = 0.0026$  and  $p = 0.0343$  for 60 °.s<sup>-1</sup>, 120 °.s<sup>-1</sup> and 180 °.s<sup>-1</sup>,  
330 respectively). Neither group, nor time x group effects were apparent, with the moderate  
331 improvements observed in CG following B1 at 60 °.s<sup>-1</sup> and 180 °.s<sup>-1</sup> failing to reach significance  
332 ( $p > 0.05$ , ES from 0.51 [-0.11, 1.13] to 0.65 [0.03, 1.28] – Table 3). Observed RBE for isokinetic  
333 strength was lower in CG than PLA for each velocity, as shown by significant bout x group  
334 interactions ( $p < 0.001$  to 0.0395; Tables 3 and 4). At 60 °.s<sup>-1</sup>, although performance deterioration  
335 was attenuated following B2 in both CG ( $p = 0.0336$ ) and PLA ( $p < 0.001$ ), RBE was significantly  
336 smaller in CG ( $\chi^2 = 4.24, p = 0.0395$ ; ES = -0.56 [-1.18, 0.07]; Tables 3 and 4). Conversely, the bout  
337 x group interactions observed at 120 °.s<sup>-1</sup> ( $\chi^2 = 16.2, p < 0.001$ ) and 180 °.s<sup>-1</sup> ( $\chi^2 = 10.4, p = 0.001$ )  
338 revealed that RBE was absent in CG. Whilst *post hoc* testing demonstrated greater peak forces  
339 in PLA following B2 at both 120 °.s<sup>-1</sup> and 180 °.s<sup>-1</sup> ( $p < 0.001$  for both), no increase was observed  
340 in CG ( $p = 0.875, p = 0.5507$ ; Tables 3 and 4).

341

342 A decline in PPT was observed over time ( $\chi^2 = 153, p < 0.001$ ), with peak power recovering by 48  
343 h ( $p = 1$ ). Cycle power improved over B2 compared to B1 ( $p < 0.001$ ). *Post hoc* power analyses at  
344 individual time-points following B1 yielded  $\beta$  values of 0.14–0.58 for force dynamometry, and

345 0.11–0.32 for peak cycling power. Power from observed differences for RBE between groups  
346 ranged from 0.29 to 0.86 for force dynamometry and was 0.13 for PPT.

347

348 Changes in MTG were observed over time ( $\chi^2 = 14.2, p < 0.001$ ) and between bouts ( $\chi^2 = 8.25, p$   
349  $= 0.004$ ), with mean values greater than baseline from 24 h ( $p = 0.049, p = 0.0114, \text{ and } p = 0.0382$   
350 for 24 h, 48 h and 72 h, respectively – Figure 3, Supplementary Table). Neither group x time ( $\chi^2$   
351  $= 1.15, p < 0.886$ ), three-way ( $\chi^2 = 1.26, p = 0.868$ ), nor bout x time interactions were significant  
352 ( $\chi^2 = 0.585, p = 0.630$ ). However, a bout x group effect was observed ( $\chi^2 = 6.66, p = 0.01$ ), with  
353 *post hoc* testing demonstrating that swelling in CG was greater following B2, when compression  
354 was not worn ( $p < 0.001$ ). Conversely, swelling did not differ between bouts in PLA ( $p = 0.984$ ).  
355 Soreness (Figure3) changed over time ( $\chi^2 = 2.87, p < 0.001$ ), and between bouts ( $\chi^2 = 62.8, p <$   
356  $0.001$ ), and demonstrated a significant time x bout interaction ( $\chi^2 = 6.3, p < 0.001$ ). No significant  
357 differences or interactions between groups were apparent ( $p > 0.05$ ). *Post hoc* testing revealed  
358 that while soreness remained elevated from baseline at all times during B1 ( $p < 0.001$ ), values  
359 returned to baseline by 72 h in B2 ( $p = 0.151$ ).

360

361 In addition to participant attrition, CK analysis was limited further by insufficient blood samples  
362 from one participant, with a further two participants giving anomalous pre-exercise readings.  
363 Technical error was ruled out by analysing dilutions of the original sample, which all indicated  
364 similar CK activity (within 1–15%), while elevated baseline readings did not reflect impaired  
365 muscular performance compared to the previous/subsequent bout. These anomalous readings  
366 resulted in between-bout differences at least 3-times greater than the group SD of the  
367 differences (exceeding the 99% confidence interval), so were removed from the analysis.  
368 Creatine kinase activity in the resulting 28 participants changed over time ( $\chi^2 = 16.7, p = 0.002$ ),  
369 and between bouts ( $\chi^2 = 12.1, p < 0.001$ ), with no other differences or interactions observed ( $p$   
370  $> 0.05$ ). Hypothesis testing was not affected by the inclusion or exclusion of the anomalous  
371 results (main effects for set and bout;  $\chi^2 = 11.9, p = 0.0179$  and  $\chi^2 = 13.3, p < 0.001$ , respectively).  
372 *Post hoc* testing revealed that average values at 24 h were greater than those recorded at both  
373 pre-exercise ( $p = 0.0124$ ) and post-exercise ( $p = 0.0444$ ) time points.

374

375

376 **Table 1. Participant characteristics**

	<b>CG</b>	<b>PLA</b>	
<b>Age (y)</b>	27.3 ± 6.7	25.1 ± 8.5	377
<b>Body mass (kg)</b>	77 ± 11.3	78.1 ± 10.4d	378
<b>Stature (m)</b>	1.78 ± 0.1	1.77 ± 0.1	
<b>Σ8 skinfolds (mm)</b>	89 ± 44.8	112 ± 55.5	379
<b>MVIC (N)</b>	639 ± 122	635 ± 141	
<b>MTG (cm)</b>	55.3 ± 5.9	54.5 ± 4.5	380
<b>Calf (cm)</b>	37.5 ± 2	39.7 ± 8.5	
<b>CG Pressure (mmHg)</b>			381
<b>Thigh</b>	16 ± 3		
<b>Calf</b>	23 ± 6		382
<b>MB1</b>	21 ± 5		
<b>Ankle</b>	16 ± 2		383

384 CG = Compression garments; PLA = Placebo; MVIC = Maximal isometric voluntary contraction,  
385 MTG = Mid-thigh girth; Calf = Medial calf (circumference or site for interface pressure  
386 measurement); Thigh = Mid-thigh skinfold site; Calf = point of widest circumference at the  
387 medial calf; MB1 = Manufacturer's B1 point; Ankle = Interface pressure taken at point of  
388 narrowest circumference of the ankle

389

390

391

392

393

394

395

396

397

398

399

400 **Table 2. Exercise responses from a combined repeated-sprint (20 x 20 m) and depth-jump (10**  
 401 **x 10) muscle-damage protocol**

	CG		PLA	
	B1	B2	B1	B2
<b>Repeated sprints</b>				
<b>20 m sprint time (s)</b>	3.66 ± 0.47	3.56 ± 0.27	3.53 ± 0.2	3.5 ± 0.24
<b>HR<sub>med</sub> (beats.min<sup>-1</sup>)</b>	146 ± 15	144 ± 20	144 ± 21	140 ± 19
<b>HR<sub>pk</sub> (beats.min<sup>-1</sup>)</b>	155 ± 15	148 ± 15	154 ± 18	151 ± 17
<b>Depth-jumps</b>				
<b>Breaking F<sub>pk</sub> (N)</b>	4463 ± 1005	4263 ± 710	4743 ± 895	4606 ± 857
<b>Breaking F<sub>ave</sub> (N)</b>	1424 ± 123	1421 ± 75	1436 ± 67	1447 ± 77
<b>Propulsive F<sub>pk</sub> (N)</b>	1648 ± 198	1682 ± 211	1600 ± 207	1631 ± 207
<b>Propulsive F<sub>ave</sub> (N)</b>	1085 ± 99	1086 ± 58	1075 ± 72	1046 ± 62
<b>Jump Height TOV (cm)</b>	13 ± 2	13 ± 1	12 ± 1	13 ± 1
<b>Total work (J)</b>	176904 ± 284	184384 ± 173	163703 ± 167	176416 ± 184
<b>Total work (J.kg<sup>-1</sup> per jump)</b>	23 ± 4	24 ± 2	22 ± 2	22 ± 2
<b>HR<sub>med</sub> (beats.min<sup>-1</sup>)</b>	156 ± 14	150 ± 16	153 ± 18	152 ± 18
<b>HR<sub>pk</sub> (beats.min<sup>-1</sup>)</b>	170 ± 12	164 ± 16	166 ± 16	166 ± 18

402 CG = Compression garments; PLA = Placebo; B1 = Bout 1; B2 = Repeated bout; HR<sub>med</sub> = Median  
 403 heart-rate; HR<sub>pk</sub> = Peak heart-rate; F<sub>pk</sub> = Peak force; F<sub>ave</sub> = Average force; TOV = As calculated  
 404 from take-off velocity

405

406

407

408

409

410

411


412

413

414


415





429 **Figure 2. Peak maximal voluntary contraction force for isometric (MVIC) and isokinetic**  
 430 **contractions at 60 °.s<sup>-1</sup>, 120 °.s<sup>-1</sup>, 180 °.s<sup>-1</sup>, over an initial (left) and repeated bout (right) of**  
 431 **eccentrically-focused exercise**

432 Black line and crosses = Compression garments; Grey line and diamonds = Placebo; \* =  
 433 Significant effect of time ( $p < 0.001$  for each variable);  $\beta$  = Significant difference between bouts  
 434 ( $p < 0.001$  for each variable);  $*\beta$  = Significant time x bout interaction ( $p < 0.001$  for all isokinetic  
 435 speeds,  $p = 0.004$  for MVIC)  $\delta$  = Significant bout x group interaction ( $p = 0.0395$ ,  $p < 0.001$ ,  $p =$   
 436  $0.001$  for 60 °.s<sup>-1</sup>, 120 °.s<sup>-1</sup> and 180 °.s<sup>-1</sup>, respectively. MVIC:  $p = 0.128$ )



437

438 **Figure 3. Mid-thigh girth and soreness over an initial (left) and repeated bout (right) of**  
 439 **eccentrically-focused exercise** Black line and crosses = Compression garments; Grey line and  
 440 diamonds = Placebo; \* = Significant effect of time ( $p < 0.001$ );  $\beta$  = Significant difference  
 441 between bouts (mid-thigh girth:  $p = 0.004$ ; soreness:  $p < 0.001$ );  $\delta$  = Significant bout x group  
 442 interaction ( $p = 0.01$ );  $*\beta$  = Significant time x bout interaction ( $p < 0.001$ )

443

444

445

446

447

448

449

450

451

452

453

454

455

456 **Table 3. Effect sizes and 90% confidence limits for between group differences**

	Time	Post	24 h	48 h	72 h	RBE	Time	Post	24 h	48 h	72 h	RBE
<b>MVIC</b>		0.09	0.34	0.27	0.33	-0.38	<b>IKD</b>	0.4	0.65	0.46	0.65	-0.56
		[-0.53, 0.7]	[-0.28, 0.96]	[-0.35, 0.88]	[-0.28, 0.95]	[-1, 0.23]	<b>60<sup>0</sup>.s<sup>-1</sup></b>	[-0.22, 1.01]	[0.02, 1.27]	[-0.16, 1.08]	[0.03, 1.28]	[-1.18, 0.07]
<b>IKD</b>		0.24	0.48	0.25	0.2	-0.96	<b>IKD</b>	0.32	0.38	0.3	0.51	-0.72
<b>120<sup>0</sup>.s<sup>-1</sup></b>		[-0.38, 0.86]	[-0.14, 1.11]	[-0.36, 0.87]	[-0.41, 0.82]	[-1.61, -0.32]	<b>180<sup>0</sup>.s<sup>-1</sup></b>	[-0.29, 0.94]	[-0.24, 1]	[-0.32, 0.92]	[-0.11, 1.13]	[-1.35, -0.09]
<b>PPT</b>		0.32	0.25	0.41	0.15	0.18	<b>MTG</b>	0.4	0.65	0.46	0.65	0.16
		[-0.3, 0.94]	[-0.36, 0.87]	[-0.21, 1.03]	[-0.47, 0.76]	[-0.43, 0.8]		[-0.22, 1.01]	[0.02, 1.27]	[-0.16, 1.08]	[0.03, 1.28]	[-0.45, 0.78]
<b>Soreness</b>		-0.08	-0.39	-0.02	0.09	0.09	<b>[CK]</b>	-0.47	0.09	-0.22	-0.35	0.33
		[-0.69, 0.54]	[-1.01, 0.23]	[-0.63, 0.59]	[-0.53, 0.7]	[-0.53, 0.7]		[-1.09, 0.15]	[-0.52, 0.7]	[-0.84, 0.39]	[-0.97, 0.27]	[-0.29, 0.95]

457

458 Effect sizes (Cohen’s d) reported as ES [LCL, UCL]), where LCL and UCL represent the lower and upper 90% confidence limits. Effect size thresholds  
 459 were as follows: ≤ 0.2 (trivial), 0.2 - 0.49 (small), 0.5–0.79 (moderate), > 0.8 (large). Post = Post-exercise; RBE = Repeated bout effect (defined as the  
 460 difference between the means of the repeated and the initial bout); MVIC = Maximal voluntary isometric contraction; IKD = Maximal voluntary  
 461 isokinetic contraction; PPT = peak power output in the 6 s cycle sprint test; MTG = Mid-thigh girth; [CK] = Creatine kinase activity

462 **Discussion**

463 The present study investigated the effects of CG on recovery and adaptation following EIMD.  
464 Whilst the effects of CG on recovery were not significant, RBE for isokinetic performance was  
465 impaired each velocity. Although these findings were specific to isokinetic strength, these data  
466 provide novel and robust evidence that CG may undermine aspects of RBE in non-resistance  
467 trained males.

468

469 The current findings do not support previous studies which suggest that CG enhance recovery  
470 from EIMD (Brown et al., 2017; Hill et al., 2017; Marques-Jimenez et al., 2016; Peake, 2019).

471 These observations may be related to several discrepancies between the current study and  
472 previous trials - including differences in interface pressures, populations, and exercise  
473 protocols (Brown et al., 2017; Marques-Jimenez et al., 2016). However, as the placebo effect  
474 can enhance performance by up to 6% (ES = 1.2) (Clark et al., 2000), it is also possible that the  
475 effective blinding strategy employed was at least partly responsible (Tables 3 and 4). Effective  
476 blinding has also been postulated to explain non-significant findings on cold water immersion  
477 (CWI) which contradict those from earlier studies (Wilson et al., 2018). Furthermore, the  
478 current study was conducted double-blind to eliminate the possibility of providing  
479 subconscious cues to participants, which can further inflate treatment effects (Karanicolas et  
480 al., 2010). These data highlight the need to implement and evaluate a double-blind approach  
481 to elucidate the true effects of CG on recovery.

482

483 The non-significant effects of CG for recovery in the current study are somewhat surprising, as  
484 observed interface pressures were similar to previously proposed pressure optima. For example,  
485 benefits have been commonly observed from garments applying around 14–20 mmHg at the  
486 thigh, above or below which pressures CG may be ineffective (Hill et al., 2017; Miyamoto &  
487 Kawakami, 2014). A 15% improvement in recovery of countermovement jump performance was  
488 previously reported in recreationally active participants (Hill et al., 2017) when class II CG,  
489 providing almost identical interface pressures to those we report, were worn for 72 h following  
490 100 DJs ( $14.8 \pm 2.2$  vs  $16 \pm 3$  mmHg at the thigh and  $24.3 \pm 3.7$  vs  $23 \pm 6$  at the calf). However,  
491 pressure optima yet to be conclusively established (Brown et al., 2017; Hill et al., 2017; Hill et  
492 al., 2015). Furthermore, even directly measured interface pressures may vary with small

493 changes in sensor placement and non-uniformities in limb profile (Bjork & Ehmann, 2019),  
494 complicating comparisons between trials. Error also arises from the different sensors used, with  
495 the Kikuhime device used by Hill et al. (Hill et al., 2017) known to overestimate applied pressures  
496 by 10–15% compared to the Picropress (Partsch & Mosti, 2010). Discrepancies may also be  
497 related to differences in the recovery of jumping versus isometric performance (Byrne & Eston,  
498 2002), or the mixed sex population studied by Hill et al., considering potential sex-specific  
499 responses to EIMD (Clarkson & Hubal, 2002; Fernandez-Gonzalo et al., 2014). Further research  
500 is required to establish pressure optima for recovery, with a pressing need for researchers in the  
501 field to report directly measured pressures using standardised procedures.

502

503 The findings we present are the first to report deleterious effects from CG on muscular  
504 adaptation, contradicting previous findings which suggest variable, but likely positive effects  
505 on strength, power and endurance outcomes (Baum et al., 2020; Edgar et al., 2022). However,  
506 the adaptations underpinning RBE are likely distinct to those elicited by either hypertrophy or  
507 endurance training (Hyldahl et al., 2017). Additionally, the compression stimulus provided in  
508 the current trial likely differed from previous studies. The military recruits in Edgar's study  
509 wore compression leggings for 4–6 h.d<sup>-1</sup> only, with reported interface pressures ( $15.0 \pm 4.3$  and  
510  $11.8 \pm 3.1$  mmHg at the thigh, before and after the training intervention, respectively)  
511 measured with the Kikuhime. No placebo was given to the control group. Conversely, Baum et  
512 al. (2020) studied the effects of sports compression leggings worn *during* training (pressures  
513 not reported), presumably to investigate the cumulative effects of enhanced training  
514 performance. The data we present suggest the negative effects of medical-grade CG on RBE  
515 are greater than any potential benefits for recovery following unaccustomed exercise in non-  
516 resistance trained males.

517

518 The current findings are the first to demonstrate negative effects from compression on  
519 adaptation – specifically on RBE for isokinetic strength. Furthermore, these effects appear to  
520 be velocity-specific, with RBE reduced at  $60^\circ.s^{-1}$ , but completely absent in CG at  $120^\circ.s^{-1}$  and  
521  $180^\circ.s^{-1}$ . That these observations were made following the use of an effective placebo  
522 intervention, double-blind design, and reported alongside a reduction in swelling following B1  
523 strengthens the case for a physiologically-mediated effect of CG, with the combined alpha  
524 value from all three isokinetic interactions equating to  $p < 3.95 \times 10^{-8}$ . These findings are also

525 concordant with previous observations that protective adaptations to EIMD are associated  
526 with a greater relative recruitment of oxidative motor-units and subsequent preservation of  
527 high velocity performance (Hinks et al., 2021; Hortobagyi et al., 1996; Hyldahl et al., 2017). In  
528 the current study, however, these adaptations were absent in CG. Although it is important to  
529 note that no other indices of EIMD were blunted (e.g. isometric strength or CK), these findings  
530 have important implications for the use of compression throughout unaccustomed training.  
531 The utility of strength training for improving high-velocity performance is well established  
532 (Cronin, Ogden, Lawton, & Brughelli, 2007; García-Valverde, Manresa-Rocamora, Hernández-  
533 Davó, & Sabido, 2022), with greater isokinetic strength commonly associated with improved  
534 power performance in active and athletic populations (Janicijevic, Knezevic, Garcia-Ramos,  
535 Cvetić, & Mirkov, 2020; Moreira et al., 2021).

536

537 Whilst the mechanisms involved were not explicitly investigated, nor inflammation directly  
538 measured, several physiological observations in the current study are concordant with previous  
539 findings suggesting that CG reduce tissue damage by moderating inflammation (Beidler et al.,  
540 2009; Valle et al., 2013). Interestingly, impaired RBE in CG was observed following an attenuated  
541 swelling response after B1 (Figures 2-3). As swelling is known to propagate the inflammatory  
542 response by facilitating leukocyte adhesion (Lawrence & Springer, 1991), and RBE is thought to  
543 be mediated by inflammation (Deyhle et al., 2016; Figueiredo et al., 2016), it is possible these  
544 two observations are related. Although CG have not been shown to reliably reduce circulating  
545 inflammatory markers when worn for recovery (Duffield et al., 2010; Hill et al., 2017; Peake,  
546 2019), previous findings suggest CG can moderate leukocyte infiltration; which was reduced in  
547 professional footballers 48 h after CG were worn *during* downhill-running (Valle et al., 2013).  
548 Research is required to establish the biochemical effects of compression, the relevance to  
549 recovery and specific adaptations.

550

### 551 **Limitations**

552 The current study is subject to a number of important limitations; most notably the small  
553 sample size. The double-blind (initially pair-matched) design made it inappropriate to replace  
554 participants who withdrew, while the initial sample size was calculated from single blind  
555 studies, which may overestimate treatment effects (Karanicolas et al., 2010). Interestingly,  
556 isokinetic performance at baseline was lower in B2 at all three velocities, despite the fact that

557 RBE manifested as greater mean values over B2 due to more rapid recovery. This may suggest  
558 that either recovery following B1 was incomplete, or that having undergone a previous bout of  
559 damaging exercise, participants were dissuaded from providing maximal efforts. Indeed, an  
560 apparent trend for lower baseline performance in a repeated bout has been reported  
561 previously (Falvo, Schilling, & Smith, 2010). However, it is important to note that this lower  
562 baseline for B2 did not differ between groups (no three-way interaction), and was not  
563 observed for MIVC (a criterion measure for assessing EIMD). As such, this observation does not  
564 affect our conclusion - that RBE was attenuated in CG.

565

566 Another limitation of the current study is the loss of CK data, which may also have masked  
567 meaningful differences. The non-significant 31-62% reductions in CG are perhaps noteworthy  
568 considering the variable nature of this measure (Clarkson & Hubal, 2002; Hill et al., 2017;  
569 Paschalis et al., 2005). Individual EIMD responses were also highly variable, with pre-post  
570 declines in isometric strength varying from 5.3% to 59.6% in this sample. Similarly, the lack of  
571 effects from CG on soreness are also likely due in part to the highly subjective nature of this  
572 measure (Fitzgerald, Rothstein, Mayhew, & Lamb, 1991). Finally, as RBE is population and  
573 exercise specific (Hyldahl et al., 2017) it would be unwise to extrapolate these findings to other  
574 scenarios. Research on females and studies investigating the effects of compression pressure  
575 on strength and endurance adaptations are required.

576

## 577 **Conclusion**

578 Compression garments did not enhance muscular recovery in non-resistance trained males,  
579 although RBE for isokinetic strength was impaired. These findings provide the only evidence to  
580 date that the use of CG attenuates muscular adaptation. Based on these findings, the use of  
581 CG for recovery would not be recommended following unaccustomed exercise, particularly if  
582 the maintenance of high-velocity performance, and resilience to EIMD are desirable.

583

584

585

586

587

588

589 **References**

- 590 Batterham, A. M., & Hopkins, W. G. (2006). Making meaningful inferences about magnitudes.  
591 *International journal of sports physiology and performance*, 2(1), 50-57.
- 592 Baum, J. T., Carter, R. P., Neufeld, E. V., & Dolezal, B. A. (2020). Donning a novel lower-limb  
593 restrictive compression garment during training augments muscle power and strength.  
594 *International Journal of Exercise Science*, 13(3), 890.
- 595 Beidler, S. K., Douillet, C. D., Berndt, D. F., Keagy, B. A., Rich, P. B., & Marston, W. A. (2009).  
596 Inflammatory cytokine levels in chronic venous insufficiency ulcer tissue before and  
597 after compression therapy. *Journal of Vascular Surgery*, 49(4), 1013-1020.
- 598 Bjork, R., & Ehmann, S. (2019). STRIDE Professional guide to compression garment selection for  
599 the lower extremity. *Journal of Wound Care*, 28(Sup6a), 1-44.
- 600 Brown, F., Gissane, C., Howatson, G., van Someren, K., Pedlar, C., & Hill, J. (2017). Compression  
601 garments and recovery from exercise: a meta-analysis. *Sports Medicine*, 47(11), 2245-  
602 2267.
- 603 Brown, F., Hill, M., Renshaw, D., Pedlar, C., Hill, J., & Tallis, J. (2022). Test–retest reliability of  
604 muscular performance tests and compression garment interface pressure  
605 measurements: a comparison between consecutive and multiple day recovery. *Sports*  
606 *Engineering*, 26(1).
- 607 Brown, F. C., Hill, J. A., van Someren, K., Howatson, G., & Pedlar, C. R. (2021). The effect of  
608 custom-fitted compression garments worn overnight for recovery from judo training in  
609 elite athletes. *European Journal of Sport Science*, 1-9.
- 610 Byrne, C., & Eston, R. (2002). The effect of exercise-induced muscle damage on isometric and  
611 dynamic knee extensor strength and vertical jump performance. *Journal of Sports*  
612 *Sciences*, 20(5), 417-425.
- 613 Care, D. o. H. a. S. (2019). Physical activity guidelines: UK chief medical officers' report. In:  
614 Department of Health and Social Care London, UK.
- 615 Chen, T. C., & Nosaka, K. (2006). Effects of number of eccentric muscle actions on first and  
616 second bouts of eccentric exercise of the elbow flexors. *Journal of Science and*  
617 *Medicine in Sport*, 9(1-2), 57-66.
- 618 Clark, V. R., Hopkins, W. G., Hawley, J. A., & Burke, L. M. (2000). Placebo effect of carbohydrate  
619 feedings during a 40-km cycling time trial. *Medicine & Science in Sports & Exercise*,  
620 32(9), 1642-1647.
- 621 Clarkson, P. M., & Hubal, M. J. (2002). Exercise-induced muscle damage in humans. *American*  
622 *Journal of Physical Medicine & Rehabilitation*, 81(11 Suppl), S52-69.
- 623 Cronin, J., Ogden, T., Lawton, T., & Brughelli, M. (2007). Does increasing maximal strength  
624 improve sprint running performance? *Strength and Conditioning Journal*, 29(3), 86-95.
- 625 de Glanville, K. M., & Hamlin, M. J. (2012). Positive effect of lower body compression garments  
626 on subsequent 40-kM cycling time trial performance. *The Journal of Strength &*  
627 *Conditioning Research*, 26(2), 480-486.
- 628 Deyhle, M. R., Gier, A. M., Evans, K. C., Eggett, D. L., Nelson, W. B., Parcell, A. C., & Hyldahl, R.  
629 D. (2016). Skeletal muscle inflammation following repeated bouts of lengthening  
630 contractions in humans. *Frontiers in Physiology*, 6, 424-424.
- 631 Duffield, R., Cannon, J., & King, M. (2010). The effects of compression garments on recovery of  
632 muscle performance following high-intensity sprint and plyometric exercise. *Journal of*  
633 *Science and Medicine in Sport*, 13(1), 136-140.
- 634 Edgar, D. T., Beaven, C. M., Gill, N. D., & Driller, M. W. (2022). Under Pressure: the chronic  
635 effects of lower-body compression garment use during a 6-week military training  
636 course. *International Journal of Environmental Research and Public Health*, 19(7),  
637 3912.



- 638 Falvo, M., Schilling, B., & Smith, A. (2010). Repeated bout effect is absent in resistance trained  
639 men. An electromyographic analysis. *Journal of Electromyography and Kinesiology*,  
640 19(6), e529-e535.
- 641 Fernandez-Gonzalo, R., Lundberg, T. R., Alvarez-Alvarez, L., & de Paz, J. A. (2014). Muscle  
642 damage responses and adaptations to eccentric-overload resistance exercise in men  
643 and women. *European journal of applied physiology*, 114(5), 1075-1084.
- 644 Feys, J. (2016). Nonparametric Tests for the Interaction in Two-way Factorial Designs Using R. *R*  
645 *Journal*, 8(1), 367-378.
- 646 Figueiredo, V. C., Roberts, L. A., Markworth, J. F., Barnett, M. P., Coombes, J. S., Raastad, T.,  
647 Peake, J. M., & Cameron-Smith, D. (2016). Impact of resistance exercise on ribosome  
648 biogenesis is acutely regulated by post-exercise recovery strategies. *Physiological*  
649 *reports*, 4(2), e12670.
- 650 Fitzgerald, G. K., Rothstein, J. M., Mayhew, T. P., & Lamb, R. L. (1991). Exercise-induced muscle  
651 soreness after concentric and eccentric isokinetic contractions. *Physical Therapy*,  
652 71(7), 505-513.
- 653 Flack, K. D., Johnson, L., & Roemmich, J. N. (2017). Aerobic and resistance exercise  
654 reinforcement and discomfort tolerance predict meeting activity guidelines. *Physiology*  
655 *& Behavior*, 170, 32-36.
- 656 Gandotra, K., Jaskiw, G. E., Williams, S. G., Fuller, M. A., Chen, P., Wilson, B., ElGhoul, R.,  
657 Konicki, E., & Strohl, K. P. (2021). Development of insomnia associated with different  
658 formulations of bupropion. *The Primary Care Companion for CNS Disorders*, 23(1),  
659 25958.
- 660 García-Valverde, A., Manresa-Rocamora, A., Hernández-Davó, J. L., & Sabido, R. (2022). Effect  
661 of weightlifting training on jumping ability, sprinting performance and squat strength:  
662 A systematic review and meta-analysis. *International Journal of Sports Science &*  
663 *Coaching*, 17(4), 917-939.
- 664 Goto, K., & Morishima, T. (2014). Compression garment promotes muscular strength recovery  
665 after resistance exercise. *Medicine & Science in Sports & Exercise*, 46(12), 2265-2270.
- 666 Hill, J., Howatson, G., van Someren, K., Gaze, D., Legg, H., Lineham, J., & Pedlar, C. (2017).  
667 Effects of compression garment pressure on recovery from strenuous exercise.  
668 *International journal of sports physiology and performance*, 1-22.
- 669 Hill, J. A., Howatson, G., van Someren, K. A., Davidson, S., & Pedlar, C. R. (2015). The variation  
670 in pressures exerted by commercially available compression garments. *Sports*  
671 *Engineering*, 18(2), 115-121.
- 672 Hinks, A., Hess, A., Debenham, M. I. B., Chen, J., Mazara, N., Inkol, K. A., Cervone, D. T., Spriet,  
673 L. L., Dalton, B. H., & Power, G. A. (2021). Power loss is attenuated following a second  
674 bout of high-intensity eccentric contractions due to the repeated bout effect's  
675 protection of rate of torque and velocity development. *Applied Physiology, Nutrition,*  
676 *and Metabolism*, 46(5), 461-472.
- 677 Hortobagyi, T., Hill, J. P., Houmard, J. A., Fraser, D. D., Lambert, N. J., & Israel, R. G. (1996).  
678 Adaptive responses to muscle lengthening and shortening in humans. *Journal of*  
679 *Applied Physiology*, 80(3), 765-772.
- 680 Hyldahl, R. D., Chen, T. C., & Nosaka, K. (2017). Mechanisms and mediators of the skeletal  
681 muscle repeated bout effect. *Exercise and Sport Sciences Reviews*, 45(1), 24-33.
- 682 Janicijevic, D., Knezevic, O. M., Garcia-Ramos, A., Cvetic, D., & Mirkov, D. M. (2020). Isokinetic  
683 Testing: Sensitivity of the Force-Velocity Relationship Assessed through the Two-Point  
684 Method to Discriminate between Muscle Groups and Participants' Physical Activity  
685 Levels. *Int J Environ Res Public Health*, 17(22).
- 686 Karanicolas, P. J., Farrokhyar, F., & Bhandari, M. (2010). Blinding: who, what, when, why, how?  
687 *Canadian Journal of Surgery*, 53(5), 345.

- 688 Lawrence, M. B., & Springer, T. A. (1991). Leukocytes roll on a selectin at physiologic flow  
689 rates: distinction from and prerequisite for adhesion through integrins. *Cell*, *65*(5),  
690 859-873.
- 691 Marques-Jimenez, D., Calleja-Gonzalez, J., Arratibel, I., Delextrat, A., & Terrados, N. (2016). Are  
692 compression garments effective for the recovery of exercise-induced muscle damage?  
693 A systematic review with meta-analysis. *Physiology & Behavior*, *153*, 133-148.
- 694 McMahan, J. J., Lake, J. P., Stratford, C., & Comfort, P. J. B. (2021). A proposed method for  
695 evaluating drop jump performance with one force platform. *Biomechanics*, *1*(2), 178-  
696 189.
- 697 Miyamoto, N., & Kawakami, Y. (2014). Effect of pressure intensity of compression short-tight  
698 on fatigue of thigh muscles. *Medicine & Science in Sports & Exercise*, *46*(11), 2168-  
699 2174.
- 700 Moreira, P. V. S., Falco, C., Menegaldo, L. L., Goethel, M. F., De Paula, L. V., & Gonçalves, M.  
701 (2021). Are isokinetic leg torques and kick velocity reliable predictors of competitive  
702 level in taekwondo athletes? *PLoS One*, *16*(6), e0235582.
- 703 Nich, C., & Carroll, K. (2002). 'Intention-to-treat' meets 'missing data': implications of alternate  
704 strategies for analyzing clinical trials data. *Drug and Alcohol Dependence*, *68*(2), 121-  
705 130.
- 706 Nosaka, K., Chapman, D., Newton, M., & Sacco, P. (2006). Is isometric strength loss  
707 immediately after eccentric exercise related to changes in indirect markers of muscle  
708 damage? *Applied Physiology, Nutrition, and Metabolism*, *31*(3), 313-319.
- 709 Partsch, H., & Mosti, G. (2010). Comparison of three portable instruments to measure  
710 compression pressure. *International angiology: a journal of the International Union of*  
711 *Angiology*, *29*(5), 426-430.
- 712 Paschalis, V., Koutedakis, Y., Jamurtas, A. Z., Mougios, V., & Baltzopoulos, V. (2005). Equal  
713 volumes of high and low intensity of eccentric exercise in relation to muscle damage  
714 and performance. *The Journal of Strength & Conditioning Research*, *19*(1), 184-188.
- 715 Peake, J. M. (2019). Recovery after exercise: what is the current state of play? *Current Opinion*  
716 *in Physiology*, *10*, 17-26.
- 717 Skorski, S., Mujika, I., Bosquet, L., Meeusen, R., Coutts, A. J., & Meyer, T. (2019). The temporal  
718 relationship between exercise, recovery processes, and changes in performance.  
719 *International Journal of Sports Physiology and Performance*, *14*(8), 1015-1021.
- 720 Thomas, T. R., Ziogas, G., Smith, T., Zhang, Q., & Londeree, B. R. (1995). Physiological and  
721 perceived exertion responses to six modes of submaximal exercise. *Research Quarterly*  
722 *for Exercise and Sport*, *66*(3), 239-246.
- 723 Uhl, J.-F., Benigni, J.-P., & Cornu-Thenard, A. (2013). Where should stiffness be measured in  
724 vivo? *Veins and Lymphatics*, e5-e5.
- 725 Valle, X., Til, L., Drobic, F., Turmo, A., Montoro, J. B., Valero, O., & Artells, R. (2013).  
726 Compression garments to prevent delayed onset muscle soreness in soccer players.  
727 *Muscles Ligaments Tendons Journal*, *3*(4), 295-302.
- 728 Wilson, L. J., Cockburn, E., Paice, K., Sinclair, S., Faki, T., Hills, F. A., Gondek, M. B., Wood, A., &  
729 Dimitriou, L. (2018). Recovery following a marathon: a comparison of cold water  
730 immersion, whole body cryotherapy and a placebo control. *European journal of*  
731 *applied physiology*, *118*(1), 153-163.

732

### **Acknowledgments**

Sincere thanks must go to those who patiently provided technical support and expertise at Coventry University; namely Rick Varnham and Dr. Ben Lee. Thanks as well to Dr. Peter Mundy and Jack Lineham for their guidance on biomechanics in the early stages of the project.

### **Author contributions**

FB, HJ, CP, GH and KvS conceived and designed the research. FB conducted experiments, acquiring and analysing all data, with JT contributing analytical tools, before FB, JT, MH, DR, GH and KvS all contributed to interpreting the results. FB analysed data and wrote the manuscript, with support in drafting, and critically revising the article provided by all authors.

All authors approved the final version of the manuscript, agree to be accountable for all aspects of the work, and qualify for authorship due to their contributions listed above. All those who qualify for authorship are listed.

### **Conflict of interests**

The authors did not receive support or funding from any organization for the submitted work, and have no competing interests to declare.

Supplementary Table. Raw and relative values for indices of muscle damage over time

Measure	Time	Bout 1					Bout 2					T <i>p</i>	B <i>p</i>	T x B <i>p</i>	G x B <i>p</i>
		Pre	Post	24 h	48 h	72 h	Pre	Post	24 h	48 h	72 h				
MVIC (N)	CG	639 ± 122	465 ± 115	513 ± 126	563 ± 140	606 ± 139	646 ± 128	514 ± 137	604 ± 146	637 ± 139	644 ± 161				
	PLA	635 ± 141	453 ± 130	480 ± 135	531 ± 138	563 ± 129	661 ± 135	502 ± 137	577 ± 141	622 ± 142	638 ± 138	***	***	**	
IKD 60°.s <sup>-1</sup> (N)	CG	560 ± 115	440 ± 100	466 ± 102	479 ± 107	510 ± 106	528 ± 89	459 ± 108	494 ± 121	511 ± 119	516 ± 125				
	PLA	611 ± 123	450 ± 102	450 ± 132	485 ± 137	498 ± 111	559 ± 108	455 ± 109	528 ± 111	546 ± 109	560 ± 104	***	***	***	*
IKD 120°.s <sup>-1</sup> (N)	CG	518 ± 98	413 ± 92	433 ± 104	442 ± 112	472 ± 121	468 ± 104	416 ± 109	454 ± 119	451 ± 107	466 ± 113				
	PLA	542 ± 112	419 ± 100	419 ± 105	442 ± 122	473 ± 105	516 ± 97	439 ± 90	486 ± 82	488 ± 106	514 ± 111	***	***	***	***
IKD 180°.s <sup>-1</sup> (N)	CG	480 ± 81	403 ± 76	413 ± 80	419 ± 98	451 ± 94	450 ± 72	395 ± 97	438 ± 99	429 ± 98	448 ± 91				
	PLA	504 ± 92	411 ± 90	409 ± 104	419 ± 96	436 ± 102	470 ± 88	419 ± 77	462 ± 58	465 ± 78	477 ± 83	***	***	***	***
PPT (W)	CG	1016 ± 205	918 ± 211	964 ± 221	1010 ± 223	1027 ± 217	1058 ± 232	990 ± 220	1061 ± 240	1079 ± 223	1101 ± 226				
	PLA	1017 ± 146	884 ± 184	941 ± 163	975 ± 141	1014 ± 144	1038 ± 154	947 ± 155	1021 ± 171	1046 ± 154	1069 ± 149	***	***		
MTG (cm)	CG	54.5 ± 4.5	54.8 ± 4.5	54.8 ± 4.5	54.9 ± 4.5	54.9 ± 4.7	54.7 ± 4.8	55 ± 4.9	54.9 ± 4.8	55 ± 4.8	54.9 ± 4.9				
	PLA	55.5 ± 4.4	55.8 ± 4.4	56.1 ± 4.6	56.2 ± 4.6	56.1 ± 4.7	55.9 ± 4	56.1 ± 3.9	56.1 ± 4	56.1 ± 4	56.1 ± 4	***	**		**
SOR (AU)	CG	1.2 ± 1.3	4.8 ± 2.4	5.1 ± 2	5 ± 2.1	3.1 ± 1.8	0.5 ± 0.5	3.5 ± 2.4	3.3 ± 1.8	2.6 ± 1.8	1.4 ± 1.3				
	PLA	1 ± 1.1	5 ± 2.3	5.9 ± 2.1	5 ± 2.3	2.9 ± 1.5	0.6 ± 0.7	3.4 ± 2.2	3.4 ± 1.9	2.4 ± 1.6	1.4 ± 1.4	***	***	***	
[CK] (IU)	CG	264 ± 189	347 ± 226	1351 ± 1372	833 ± 839	672 ± 356	260 ± 160	305 ± 149	505 ± 229	380 ± 212	374 ± 447				
	PLA	360 ± 239	468 ± 228	1249 ± 1159	1205 ± 1427	1755 ± 4229	321 ± 159	398 ± 168	657 ± 283	451 ± 195	355 ± 124	**	***		

Values as percentage of baseline

Measure	Time	Bout 1					Bout 2				
		Pre	Post	24 h	48 h	72 h	Pre	Post	24 h	48 h	72 h
MVIC	CG	100 ± 0	73 ± 12	80 ± 13	88 ± 13	94 ± 12	102 ± 9	82 ± 19	95 ± 13	100 ± 12	101 ± 11
	PLA	100 ± 0	71 ± 15	76 ± 14	84 ± 15	90 ± 15	109 ± 13	83 ± 19	95 ± 20	103 ± 19	105 ± 17
IKD 60°.s <sup>-1</sup>	CG	100 ± 0	79 ± 14	84 ± 13	86 ± 12	92 ± 10	97 ± 14	84 ± 14	89 ± 13	92 ± 11	93 ± 11
	PLA	100 ± 0	74 ± 11	74 ± 17	79 ± 16	83 ± 16	95 ± 15	78 ± 17	90 ± 19	92 ± 13	95 ± 13
IKD 120°.s <sup>-1</sup>	CG	100 ± 0	80 ± 11	83 ± 12	85 ± 11	91 ± 13	91 ± 9	81 ± 13	88 ± 11	87 ± 10	90 ± 10
	PLA	100 ± 0	77 ± 11	78 ± 12	81 ± 15	88 ± 13	98 ± 11	84 ± 14	93 ± 10	93 ± 12	97 ± 10
IKD 180°.s <sup>-1</sup>	CG	100 ± 0	84 ± 7	86 ± 10	87 ± 12	94 ± 13	95 ± 8	83 ± 13	91 ± 12	89 ± 11	94 ± 9
	PLA	100 ± 0	81 ± 9	81 ± 15	83 ± 12	87 ± 15	96 ± 13	86 ± 13	95 ± 8	95 ± 13	98 ± 13
PPT	CG	100 ± 0	90 ± 9	95 ± 10	99 ± 9	101 ± 8	104 ± 6	98 ± 11	105 ± 10	107 ± 11	109 ± 10
	PLA	100 ± 0	87 ± 13	92 ± 8	96 ± 6	100 ± 7	104 ± 9	95 ± 12	103 ± 12	105 ± 11	108 ± 10
MTG	CG	100 ± 0	100.5 ± 0.5	100.5 ± 0.6	100.6 ± 0.9	100.7 ± 0.8	100.8 ± 1.9	101.3 ± 2	101.3 ± 1.7	101.4 ± 1.8	101.2 ± 1.7
	PLA	100 ± 0	100.5 ± 0.5	101.1 ± 0.9	101.3 ± 1	101.1 ± 0.9	100.7 ± 2.9	101 ± 3	101 ± 2.8	101 ± 2.8	101 ± 2.8
[CK]	CG	100 ± 0	139 ± 25	627 ± 741	402 ± 484	323 ± 228	122 ± 69	153 ± 114	255 ± 197	179 ± 105	195 ± 282
	PLA	100 ± 0	146 ± 40	495 ± 682	482 ± 646	700 ± 1692	113 ± 71	145 ± 84	244 ± 175	159 ± 97	129 ± 75

Results shown as mean ± SD; \* =  $p \leq 0.05$ ; \*\* =  $p \leq 0.01$ ; \*\*\* =  $p \leq 0.001$ ; T = effect of time; B = effect of bout; T x B = Time x bout interaction; G x B = Group x bout interaction; CG = Compression garments; PLA = Placebo; Pre = Pre-exercise; Post = Post-exercise; MVIC = Maximal voluntary isometric contraction; IKD = Maximal voluntary isokinetic contraction; PPT = peak power output in the 6 s cycle sprint test; MTG = Mid-thigh girth; AU = Arbitrary units; [CK] = Creatine kinase activity; IU = International units

## **Abbreviations**

ANOVA: Analysis of variance

B1: Initial exercise bout

B2: Repeated exercise bout

CG: Compression garments

CI: Confidence intervals

CK: Creatine kinase

CV: Coefficient of variation

DJ: Depth-jumps

EIMD: Exercise-induced muscle damage

ES: Effect size (Cohen's d)

F<sub>ave</sub>: Average force

F<sub>pk</sub>: Peak force

HR<sub>med</sub>: Median heart rate

HR<sub>pk</sub>: Peak heart rate

IKD: Maximal voluntary isokinetic contraction

LCL: Lower confidence limit

MB1: Manufacturer's B1 point, defined as equidistant between the point of narrowest circumference at the ankle, and the point of maximal calf circumference

MIVC: Maximal isometric voluntary contractions

MTG: Mid-thigh girth

PLA: Placebo

PPT: Peak power output in the 6 s cycle sprint test

RBE: Repeated bout effect

RMSE: Root mean squared error of residuals

TOV: Take-off velocity

UCL: Upper confidence limit